
Patients fall out of surveillance pathways due to poor visibility, delayed results, and fragmented admin processes.
Automated reminders + real-time alerts + shared pathway tracking + digital patient feedback.
Higher compliance, earlier detection, reduced clinic burden, improved patient experience.
Uncertainty around patient stability prior to re-prescribing high-risk medications → unsafe decision-making.
Automated blood monitoring + clinician-defined alert thresholds + admin-led surveillance with escalation.
Safe-to-prescribe decision support, earlier detection of toxicity/deterioration, reduced clinician workload with continuous oversight.
Patients with MGUS lack ongoing visibility while on surveillance or waiting lists → risk sits unmanaged between contacts.
Automated blood test surveillance with pathway-based reminders and tracking.
Improved visibility of patient status, safer waiting list management, reduced clinical burden through admin-led monitoring.
PSA follow-up is inconsistent → missed tests, delayed results, patient anxiety.
Automated PSA reminders + result-triggered alerts + direct patient communication.
Reliable surveillance, faster disease deterioration detection, fewer clinic visits.
Difficult to capture outcomes and audit effectively.
Digital PROMs + structured outcome tracking.
Real-time data capture, audit-ready evidence.
High-risk patients delayed due to clinic capacity constraints.
Digital monitoring alongside clinical oversight.
Faster decisions, safer high-risk patient management.
Cancelled cystoscopies not rebooked → missed critical surveillance.
Real-time tracking of procedures with cancellation alerts.
No lost follow-ups, maintained surveillance timelines.
Duplicate scan requests + unclear tracking → wasted capacity.
Centralised scan tracking + admin-led validation.
Reduced duplication, clearer oversight, freed-up clinical time.
Patients miss CEA tests, colonoscopies, and scans → pathway breakdown.
Scheduled multi-test reminders + escalation alerts.
Improved compliance, fewer missed diagnostics, safer surveillance.
Long gaps in patient contact → unmet needs and risk escalation.
Automated health questionnaires with direct clinical feedback loop.
Continuous engagement, earlier intervention, better support.
Large cohorts make personalised follow-up very difficult and time-consuming.
Risk-stratified contact pathways + dynamic patient allocation.
Right patient, right frequency, scalable personalised care.
Complex pathways → missed or poorly timed surveillance.
Editable, pathway-driven alerting aligned to treatment plans.
Accurate, adaptable follow-up across changing pathways.
Clinic time too limited for holistic review.
Pre-appointment digital assessments.
More focused consultations, better clinical efficiency.
Complex pathways + heavy admin burden on clinicians.
Digitised pathways + admin-managed alerts.
Reduced clinician workload, improved coordination.
Patients move between teams → duplication and unclear ownership.
Clear pathway ownership + transfer tracking.
Eliminates duplication, clarifies responsibility.
Low engagement cohort → high DNA and non-compliance.
Persistent automated reminders + structured follow-up.
Reduced DNAs, consistent surveillance adherence.
“For us it’s the flexibility of beetroot that serves us really well. We know that we can use it in various different ways supporting different tumour sites which are very different”
Katy Low, Assistant Director of Nursing, Cancer Division
copyright © 2026 · THERAPYAUDIT Limited All rights reserved beetroot® is a Registered Mark